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Even with these sensitive tests VTEC infection was only
demonstrated in some cases.
For the investigation of HUS every effort should be made to
detect VTEC infection. However, in cases where VTEC cannot be
isolated and no faecal verocytotoxin found alternative tests must be
considered. One such test for implicating E coli 0157 is to
demonstrate a serum antibody response. Sera from 13 patients with
HUS and from whom E coli 0157 had been isolated and 8 healthy
controls were examined for antibodies to E coli 0157 antigens by
sodium dodecyl sulphate-polyacrylamide gel electrophoresis with
immunoblotting. Sera from the patients gave a strong IgM
antibody reaction with E coli 0 157 lipopolysaccharide (LPS), while
control sera did not react with 0157 LPS.
Dr Kavi and Dr Rose (May 28, p 1224) raise concern about the
validity of using serum antibodies to identify the aetiological
infective agent in HUS. Antibody cross-reactions between the
0-antigens of E coli 0 157, Yersinia enterocolitica (0:9), and Brucella
abortus may be possible since the LPS of these bacteria share
common sugar sequences Indeed antigenic cross-reactions have
been demonstrated with bacterial agglutination tests between
strains of B abortus and Y enterocolitica (0:9),45 and between
B abortus and E coli 0157 6’ On the other hand, E coli 0157 and
Y enterocolitica (0:9) did not cross-react.7,8 By immunoblotting we
found antibodies in our HUS patients’ sera which reacted strongly
with the LPS of B abortus but not with the LPS of Y enterocolitica
(0:9), which agrees with Notenboom et al .7
Our studies and the published reports indicate that the major
source of antibody cross-reaction is between the LPS of E coli 0157
and B abortus, and probably not between E coli 0157 and Y
enterocolitica. The use of a serological test to implicate a particular
microbe as a cause of HUS is inconclusive and serological results
should be considered carefully and interpreted in relation to the
patient’s symptoms.
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PRAZOSIN CONTRAINDICATED IN PATIENTS WITH
NARCOLEPSY
SIR,-Mignot et all have demonstrated that central
T-adrenoceptors are involved in cataplexy in dogs. Prazosin
hydrochloride, a highly selective al-adrenergic receptor antagonist
that easily crosses the blood-brain barrier, was found to be a potent
cataplexy-inducing agent in narcoleptic dogs. We contacted several
sleep centres and, after chart reviews and discussions with sleep
disorder specialists, we identified four narcoleptic patients (three in
Europe, one in the United States) who had been treated for
hypertension with prazosin.
Patient A, a 67-year-old woman, had reported a significant
worsening of her cataplexy during a 2-month period when she was
taking 2 mg prazosin twice daily. Her dosage of clomipramine, a
treatment for cataplexy, had been increased to 150 mg daily. For
reasons that are unclear, the prazosin was discontinued and replaced
by an enzyme-inhibitor-type antihypertensive drug. The ensuing
reduction in cataplectic attacks was attributed to better control of
the symptoms by clomipramine.
The other three patients were still taking prazosin. Patient B was a
59-year-old man with a history of narcolepsy and cataplexy since the
age of 19. 24 hour polygraphic monitoring had indicated two sleep
onset rapid-eye-movement (REM) periods during spontaneous
naps. He had been taking 2 mg prazosin daily since the diagnosis of
hypertension 4 years previously.
Patient C was a 63-year-old woman who had been diagnosed as
having narcolepsy/cataplexy at age 42, though she had had
symptoms since the age of 16. Nocturnal and nap monitoring
indicated sleep onset REM periods. Her hypertension had been
diagnosed 12 years earlier and she was taking 4 mg prazosin daily.
We explained that we were investigating the interaction between
hypertension and cataplexy, and patients B and C agreed to a
3-week experiment. They recorded cataplectic attacks in a daily log
that specified the number, time, duration, and severity of attacks.
Severity was characterised as mild (weakness), moderate
(involvement of one part of the body, with occasional need to sit), or
severe (collapse to the floor). Logs were checked nightly during
continuation of current medication (week 1), withdrawal of prazosin
(week 2), and resumption of prazosin at the previous dose (week 3).
Blood pressure was monitored regularly. No drug was withdrawn
without the approval of the patient’s physician, who could prescribe
an enzyme-blocker type of drug at any time if the patient requested a
return to antihypertensive medication.
Patient B had 10 attacks per day on average in the baseline week, 3
per day during the prazosin-free week, and 9 per day when prazosin
was resumed. Patient C had a baseline mean of 7 daily attacks, a
mean of 2 during week 2, and a mean of 5 daily for week 3. Patient C
reported no "complete" attack (ie, a fall) during the prazosin-free
week. Both patients were more impressed by the disappearance of
complete attacks than by the reduced number.
Patient D, seen at the University of Michigan Sleep Disorders
Center, was a 48-year-old woman with a 3-year history of
hypertension and a 2-year history of narcoleptic symptoms, which
included daytime somnolence and occasional muscle weakness. She
had been treated for 6 months with 4 mg prazosin daily and had
noted a sudden worsening of cataplexy within 3 days of the start of
that medication. When first seen at the sleep clinic she presented in a
state of virtual status cataplecticus, despite treatment by a tricyclic
drug. Aware of the research on narcoleptic dogs and prazosin,l the
sleep researcher suspected that prazosin was the culprit-and its
discontinuation led to spontaneous control of status cataplecticus,
although the patient continued to experience intermittent episodes
of partial muscle weakness triggered by emotion.
Our observations demonstrate the similarity between canine and
human cataplexy and carry a warning against prescribing
a,-adrenergic antagonists to patients with cataplexy. A survey of
660 narcoleptic patients being followed up in Stanford, California,
has revealed that 30% have hypertension.
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